<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03083613</url>
  </required_header>
  <id_info>
    <org_study_id>CH-G1-070</org_study_id>
    <nct_id>NCT03083613</nct_id>
  </id_info>
  <brief_title>Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma</brief_title>
  <official_title>Phase II Trial of Raltitrexed and Paclitaxel as Second-line Chemotherapy for Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm clinical trial.The purpose of this study is to evaluate the efficacy and
      safety of Raltitrexed and Paclitaxel as second-line chemotherapy for patients with
      unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma .The primary
      endpoint of this study is objective response rate.The secondary endpoint of this study is
      safety,progression-free survival and overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Raltitrexed is an antifolate thymidylate synthase inhibitor that has shown efficacy and good
      safety profile in the treatment of colorectal cancer. To our knowledge, there has been no
      study published with the Raltitrexed and Paclitaxel regimen as second-line chemotherapy for
      patients with unresectable or metastatic gastric or gastroesophageal junction
      adenocarcinoma.The aim of our study was to evaluate the efficacy, safety and survival of this
      regimen in patients with unresectable or metastatic gastric or gastroesophageal junction
      adenocarcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>18-26 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>18-26 months</time_frame>
    <description>From date of randomization until date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>18-26 months</time_frame>
    <description>From date of randomization until date of first documented PD, date of death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Raltitrexed and Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients receive the combination therapy of Raltitrexed and Paclitaxel for a maximum of 6 cycles
Raltitrexed:3mg/m2,d1 Paclitaxel:80mg/m2,d1,d8,
Eery 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltitrexed</intervention_name>
    <description>Raltitrexed:3mg/m2,iv,d1, Every 3 weeks</description>
    <arm_group_label>Raltitrexed and Paclitaxel</arm_group_label>
    <other_name>RTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel:80mg/m2,iv,d1,d8, Every 3 weeks</description>
    <arm_group_label>Raltitrexed and Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed unresectable or metastatic gastric or
             gastroesophageal junction adenocarcinoma;

          -  Patients failed first-line chemotherapy containing fluoropyrimidines and platinums;

          -  ECOG (Eastern Cooperative Oncology Group)performance status 0-1;

          -  At least 1 measurable lesion should be present（RECIST1.1）

          -  Available Organ function: Neutrophils&gt;2g/L, Hemoglobin&gt;9g/L, Blood platelet &gt;100g/L;
             Alanine aminotransferase(ALT） and Aspartate aminotransferase(AST)&lt;1.5 ULN(upper limit
             of normal); Total bilirubin(TBIL)&lt;1.0 ULN; Cr &lt;1.0ULN

          -  Signed informed consent.

          -  Life expectancy ≥3 months;

        Exclusion Criteria:

          -  Previous treatment with Raltitrexed or Paclitaxel;

          -  Known history of allergic reaction to Raltitrexed or Paclitaxel;

          -  Known brain metastases;

          -  Pregnant or breast feeding women;

          -  Severe diarrhea,intestinal obstruction;

          -  other co-existing malignancies or malignancies diagnosed within the last 5
             years(except cured cutaneum carcinoma or carcinoma in situs of cervix);

          -  Previous myocardial infarction, unstable angina, stroke ,or uncontrollable Arrhythmia;

          -  Kown HIV infecton.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ai Ping Zhou, Doctor of medcine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ai Ping Zhou</last_name>
    <phone>8610-87788145</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>10000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ai ping Zhou</last_name>
      <phone>8610-87788145</phone>
      <email>zhouap1825@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>March 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2017</study_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Aiping Zhou</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <keyword>Raltitrexed</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>Gastroesophageal Junction Adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Raltitrexed</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

